Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05765357 | Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers | completed | Phase 1 | 89 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
| NCT03916744 | A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer | completed | Phase 1 | 75 | Genentech, Inc.INDUSTRY | 5 | Mar 10, 2023 |
| clinicaltrials |
| NCT01969643 | A Safety Study of SGN-LIV1A in Breast Cancer Patients | completed | Phase 1 | 290 | Seagen Inc.INDUSTRY | 1 | Mar 7, 2023 | clinicaltrials |
| NCT00129896 | Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients | completed | Phase 1 / Phase 2 | 73 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03689192 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | completed | Phase 1 | 13 | Herlev HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT02742935 | A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects | completed | Phase 1 | 99 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 27, 2023 | clinicaltrials |
| NCT01846091 | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer | completed | Phase 1 | 12 | Mayo ClinicOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT04514159 | A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer | completed | Phase 1 | 14 | Zeno Alpha Inc.INDUSTRY | 2 | Feb 1, 2023 | clinicaltrials |
| NCT02236000 | A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 49 | NSABP Foundation IncNETWORK | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05471648 | A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers | completed | Phase 1 | 135 | EirGenix, Inc.INDUSTRY | 1 | Jan 26, 2023 | clinicaltrials |
| NCT02652923 | Contrast Ultrasound Detection of Sentinel Lymph Nodes | completed | Phase 1 / Phase 2 | 98 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT03430479 | Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 32 | Kyoto Breast Cancer Research NetworkOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03323658 | Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2023 | clinicaltrials |
| NCT02438358 | Feasibility Study of Intraoperative Imaging in Breast Cancer | completed | Phase 1 / Phase 2 | 60 | Lumicell, Inc.INDUSTRY | 1 | Jan 5, 2023 | clinicaltrials |
| NCT04080024 | A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer(SPAGOPIX-01) | completed | Phase 1 | 14 | Spago Nanomedical ABINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT04132817 | A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread | completed | Phase 1 | 12 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 2, 2022 | clinicaltrials |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer(TOPACIO) | completed | Phase 1 / Phase 2 | 122 | Tesaro, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03344536 | A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT02479230 | Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients | completed | Phase 1 | 18 | Joseph Baar, MD, PhDOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT02627274 | A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 9 | Nov 22, 2022 | clinicaltrials |
| NCT00807859 | Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer | completed | Phase 1 | 65 | AmgenINDUSTRY | 3 | Nov 8, 2022 | clinicaltrials |
| NCT03473639 | A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy(Breast49) | completed | Phase 1 | 13 | University of VirginiaOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT01795586 | A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients | completed | Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT00623831 | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen | completed | Phase 1 | 17 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT02448771 | A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer | completed | Phase 1 / Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT03364348 | 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer | completed | Phase 1 | 18 | George W. Sledge Jr.OTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT00976131 | Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer | completed | Phase 1 | 7 | Columbia UniversityOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT01975831 | A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | completed | Phase 1 | 104 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02285179 | Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen(Poseidon) | completed | Phase 1 / Phase 2 | 189 | The Netherlands Cancer InstituteOTHER | 4 | Oct 12, 2022 | clinicaltrials |
| NCT02310464 | Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects | completed | Phase 1 | 25 | OBI Pharma, IncINDUSTRY | 1 | Oct 3, 2022 | clinicaltrials |
| NCT01676753 | Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer | completed | Phase 1 | 32 | Jo ChienOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT01730118 | Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2022 | clinicaltrials |
| NCT01791985 | AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)(RADICAL) | completed | Phase 1 / Phase 2 | 52 | Imperial College LondonOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02650817 | Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer | completed | Phase 1 | 16 | Stemline Therapeutics, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT02278965 | Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer | completed | Phase 1 | 19 | Katherine D. CrewOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT03945604 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC | completed | Phase 1 | 32 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 12, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT02657343 | An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. | completed | Phase 1 / Phase 2 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT04176757 | A Study of ZN-c5 in Participants With Breast Cancer | completed | Phase 1 | 35 | Zeno Alpha Inc.INDUSTRY | 3 | Aug 1, 2022 | clinicaltrials |
| NCT02684032 | A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer | completed | Phase 1 | 141 | Celcuity IncINDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT02719691 | Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer | completed | Phase 1 | 47 | University of Colorado, DenverOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02071862 | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | completed | Phase 1 | 210 | Calithera Biosciences, IncINDUSTRY | 1 | Jul 20, 2022 | clinicaltrials |
| NCT04261218 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer | completed | Phase 1 | 19 | Translational Research in OncologyOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT02120469 | Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer | completed | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03075462 | A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | completed | Phase 1 | 98 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT02623751 | Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer | completed | Phase 1 | 15 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04105582 | Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells | completed | Phase 1 | 5 | Universidad Nacional de ColombiaOTHER | 1 | Jun 21, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 13, 2023source: clinicaltrials